R370
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 105
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANDROGEN_RESPONSE+0.290
- MYC_TARGETS_V1+0.280
- UV_RESPONSE_DN+0.260
- PROTEIN_SECRETION+0.250
- WNT_BETA_CATENIN_SIGNALING+0.160
- TGF_BETA_SIGNALING+0.140
- MITOTIC_SPINDLE+0.110
- NOTCH_SIGNALING+0.110
- OXIDATIVE_PHOSPHORYLATION+0.110
- PEROXISOME+0.090
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.360
- INFLAMMATORY_RESPONSE-0.350
- TNFA_SIGNALING_VIA_NFKB-0.340
- IL6_JAK_STAT3_SIGNALING-0.320
- ANGIOGENESIS-0.300
- E2F_TARGETS-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- INTERFERON_ALPHA_RESPONSE-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943016 | — | — | 0.844 |
| 2 | MNG1176 | — | — | 0.838 |
| 3 | SRR26320097 | — | — | 0.828 |
| 4 | SRR12202452 | — | — | 0.826 |
| 5 | DRR168534 | — | — | 0.822 |
| 6 | 28541e4e-2e2b-4772-9566-acf35b31a581 | — | — | 0.816 |
| 7 | MDT-AP-0211 | Med | Medulloblastoma | 0.814 |
| 8 | SJEPD031010_D1.RNA-Seq | EPN | EPN Tumor | 0.809 |
| 9 | 131546 | EPN | EPN Tumor | 0.803 |
| 10 | DRR168565 | — | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.010 | Idelalisib | — uncovered |